R01 CA134660/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2009	3
2010	5
2011	6
2012	4
2013	1
2015	2
2024	0

1

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.

Weisberg E, Halilovic E, Cooke VG, Nonami A, Ren T, Sanda T, Simkin I, Yuan J, Antonakos B, Barys L, Ito M, Stone R, Galinsky I, Cowens K, Nelson E, Sattler M, Jeay S, Wuerthner JU, McDonough SM, Wiesmann M, Griffin JD. Weisberg E, et al. Mol Cancer Ther. 2015 Oct;14(10):2249-59. doi: 10.1158/1535-7163.MCT-15-0429. Epub 2015 Jul 23. Mol Cancer Ther. 2015. PMID: 26206331 Free PMC article.

2

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells.

Bhanot H, Reddy MM, Nonami A, Weisberg EL, Bonal D, Kirschmeier PT, Salgia S, Podar K, Galinsky I, Chowdary TK, Neuberg D, Tonon G, Stone RM, Asara J, Griffin JD, Sattler M. Bhanot H, et al. Leukemia. 2015 Jul;29(7):1555-1563. doi: 10.1038/leu.2015.46. Epub 2015 Feb 23. Leukemia. 2015. PMID: 25703587 Free PMC article.

3

Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases.

Toms AV, Deshpande A, McNally R, Jeong Y, Rogers JM, Kim CU, Gruner SM, Ficarro SB, Marto JA, Sattler M, Griffin JD, Eck MJ. Toms AV, et al. Nat Struct Mol Biol. 2013 Oct;20(10):1221-3. doi: 10.1038/nsmb.2673. Epub 2013 Sep 8. Nat Struct Mol Biol. 2013. PMID: 24013208 Free PMC article.

4

Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.

Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, Valent P, Hochhaus A, Hughes TP, van der Kuip H, Sattler M, Wiktor-Jedrzejczak W, Richardson C, Dorrance A, Stoklosa T, Williams DA, Skorski T. Nieborowska-Skorska M, et al. Blood. 2012 May 3;119(18):4253-63. doi: 10.1182/blood-2011-10-385658. Epub 2012 Mar 12. Blood. 2012. PMID: 22411871 Free PMC article.

5

Targeting JAK2 in the therapy of myeloproliferative neoplasms.

Reddy MM, Deshpande A, Sattler M. Reddy MM, et al. Expert Opin Ther Targets. 2012 Mar;16(3):313-24. doi: 10.1517/14728222.2012.662956. Epub 2012 Feb 17. Expert Opin Ther Targets. 2012. PMID: 22339244 Free PMC article. Review.

6

Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.

Weisberg E, Ray A, Nelson E, Adamia S, Barrett R, Sattler M, Zhang C, Daley JF, Frank D, Fox E, Griffin JD. Weisberg E, et al. PLoS One. 2011;6(9):e25351. doi: 10.1371/journal.pone.0025351. Epub 2011 Sep 28. PLoS One. 2011. PMID: 21980431 Free PMC article.

7

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.

Deshpande A, Reddy MM, Schade GO, Ray A, Chowdary TK, Griffin JD, Sattler M. Deshpande A, et al. Leukemia. 2012 Apr;26(4):708-15. doi: 10.1038/leu.2011.255. Epub 2011 Sep 16. Leukemia. 2012. PMID: 21926964 Free PMC article.

8

Aconitase regulation of erythropoiesis correlates with a novel licensing function in erythropoietin-induced ERK signaling.

Talbot AL, Bullock GC, Delehanty LL, Sattler M, Zhao ZJ, Goldfarb AN. Talbot AL, et al. PLoS One. 2011;6(8):e23850. doi: 10.1371/journal.pone.0023850. Epub 2011 Aug 22. PLoS One. 2011. PMID: 21887333 Free PMC article.

9

The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity.

Reddy MM, Fernandes MS, Deshpande A, Weisberg E, Inguilizian HV, Abdel-Wahab O, Kung AL, Levine RL, Griffin JD, Sattler M. Reddy MM, et al. Leukemia. 2012 Mar;26(3):481-9. doi: 10.1038/leu.2011.225. Epub 2011 Aug 23. Leukemia. 2012. PMID: 21860432 Free PMC article.

10

Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders.

Naramura M, Nadeau S, Mohapatra B, Ahmad G, Mukhopadhyay C, Sattler M, Raja SM, Natarajan A, Band V, Band H. Naramura M, et al. Oncotarget. 2011 Mar;2(3):245-50. doi: 10.18632/oncotarget.233. Oncotarget. 2011. PMID: 21422499 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

17 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year